MA41667A1 - Procede de diagnostic et de traitement du cancer - Google Patents

Procede de diagnostic et de traitement du cancer

Info

Publication number
MA41667A1
MA41667A1 MA41667A MA41667A MA41667A1 MA 41667 A1 MA41667 A1 MA 41667A1 MA 41667 A MA41667 A MA 41667A MA 41667 A MA41667 A MA 41667A MA 41667 A1 MA41667 A1 MA 41667A1
Authority
MA
Morocco
Prior art keywords
subject
methods
cancer
ntrk3
ntrk2
Prior art date
Application number
MA41667A
Other languages
English (en)
Inventor
Brian B Tuch
Josh Bilenker
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of MA41667A1 publication Critical patent/MA41667A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Une variété de mutations ponctuelles différentes dans ntrk1, ntrk2 et ntrk3 ont été identifiées dans des échantillons de biopsie provenant de sujets ayant une variété de cancers différents. La présente invention concerne des méthodes de traitement d'un sujet ayant un cancer, des procédés de sélection d'un traitement comprenant une quantité thérapeutiquement efficace d'un inhibiteur de trk pour un sujet, des procédés de détermination de la probabilité d'un sujet ayant un cancer de présenter une réponse positive à un traitement avec un inhibiteur de trk, des procédés de prédiction de l'efficacité d'un inhibiteur de trk chez un sujet ayant un cancer, des procédés de détermination du risque que présente un sujet de développer un cancer, et des procédés d'aide au diagnostic de cancer qui sont fondés sur l'identification d'un sujet ayant une cellule qui a au moins l'une des mutations ponctuelles dans ntrk1, ntrk2 et/ou ntrk3, ou la détermination qu'un sujet a une cellule qui présente au moins une des mutations ponctuelles dans ntrk1, ntrk2 et/ou ntrk3. L'invention concerne également des kits qui permettent la détection d'au moins l'une des mutations ponctuelles dans ntrk1, ntrk2 et/ou ntrk3.
MA41667A 2015-06-01 2016-06-01 Procede de diagnostic et de traitement du cancer MA41667A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562169443P 2015-06-01 2015-06-01
PCT/US2016/035327 WO2016196671A1 (fr) 2015-06-01 2016-06-01 Méthodes de diagnostic et de traitement du cancer

Publications (1)

Publication Number Publication Date
MA41667A1 true MA41667A1 (fr) 2018-08-31

Family

ID=56194562

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44936A MA44936A1 (fr) 2015-06-01 2016-06-01 Méthodes de diagnostic et de traitement du cancer
MA41667A MA41667A1 (fr) 2015-06-01 2016-06-01 Procede de diagnostic et de traitement du cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA44936A MA44936A1 (fr) 2015-06-01 2016-06-01 Méthodes de diagnostic et de traitement du cancer

Country Status (19)

Country Link
US (2) US20180140604A1 (fr)
EP (2) EP3722441A1 (fr)
JP (1) JP2018526324A (fr)
KR (1) KR20180021745A (fr)
CN (1) CN107849615A (fr)
AU (1) AU2016270803A1 (fr)
BR (1) BR112017025773A2 (fr)
CA (1) CA2988423A1 (fr)
CL (1) CL2017003069A1 (fr)
EA (1) EA201792679A1 (fr)
HK (1) HK1253093A1 (fr)
IL (1) IL256025A (fr)
MA (2) MA44936A1 (fr)
MX (1) MX2017015461A (fr)
PE (1) PE20180329A1 (fr)
PH (1) PH12017502200A1 (fr)
SV (1) SV2017005577A (fr)
TN (1) TN2017000502A1 (fr)
WO (1) WO2016196671A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2350075B1 (fr) 2008-09-22 2014-03-05 Array Biopharma, Inc. Composés imidazo[1,2b]pyridazine substitués comme inhibiteurs de kinases trk
HUE057625T2 (hu) 2008-10-22 2022-05-28 Array Biopharma Inc TRK kináz inhibitor szubsztituált pirazolo[1,5-a]pirimidin vegyületek
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011146336A1 (fr) 2010-05-20 2011-11-24 Array Biopharma Inc. Composés macrocycliques en tant qu'inhibiteurs de kinase trk
AU2013337277B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel NTRK1 fusion molecules and uses thereof
CA2898326C (fr) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methodes de traitement du cholangiocarcinome
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
RU2744852C2 (ru) 2015-10-26 2021-03-16 Локсо Онколоджи, Инк. Точечные мутации в устойчивых к ингибитору trk злокачественных опухолях и связанные с ними способы
AU2016370846B2 (en) * 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
WO2017176751A1 (fr) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Formulations liquides de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
JP7443057B2 (ja) 2016-05-18 2024-03-05 ロクソ オンコロジー， インコーポレイテッド （Ｓ）－Ｎ－（５－（（Ｒ）－２－（２，５－ジフルオロフェニル）ピロリジン－１－イル）－ピラゾロ［１，５－ａ］ピリミジン－３－イル）－３－ヒドロキシピロリジン－１－カルボキサミドの調製
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
KR20200031115A (ko) 2017-07-19 2020-03-23 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
US20190247398A1 (en) * 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109055562B (zh) * 2018-10-29 2022-12-20 深圳市颐康生物科技有限公司 一种生物标志物、预测肾细胞癌的复发和死亡风险的方法
US20220243280A1 (en) * 2019-05-24 2022-08-04 Foundation Medicine, Inc. Ntrk fusion molecules and uses thereof
CN110643672A (zh) * 2019-10-15 2020-01-03 西安交通大学 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途
KR20220008175A (ko) * 2020-07-13 2022-01-20 가톨릭대학교 산학협력단 전립선암 환자의 예후 진단 및 치료 전략 결정용 병리등급 특이적 마커
CN112779147A (zh) * 2020-12-23 2021-05-11 广西大学 一种流化状态对微生物聚集体微观传质及生化反应过程的测量方法及装置

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
DE60140252D1 (de) 2000-06-22 2009-12-03 Genentech Inc Agonistische monoklonale antikörper gegen trkc
US20070037150A1 (en) * 2003-02-21 2007-02-15 The Johns Hopkins University Tyrosine kinome
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
KR20080015409A (ko) 2005-05-16 2008-02-19 아스트라제네카 아베 티로신 키나제 억제제로서 유용한 피라졸릴아미노피리미딘 유도체
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
AU2006284096B2 (en) 2005-08-25 2012-03-29 Avro Life Sciences, Inc. Polymer conjugates of K-252a and derivatives thereof
CN101720322A (zh) 2007-05-04 2010-06-02 Irm责任有限公司 作为c-kit和pdgfr激酶抑制剂的化合物和组合物
KR101636312B1 (ko) 2007-07-20 2016-07-05 네르비아노 메디칼 사이언시스 에스.알.엘. 키나제 억제제로서 활성인 치환된 인다졸 유도체
CA2703329A1 (fr) 2007-10-23 2009-04-30 Novartis Ag Utilisation d'anticorps trkb pour le traitement de troubles respiratoires
JP5420568B2 (ja) 2008-01-17 2014-02-19 アイアールエム・リミテッド・ライアビリティ・カンパニー 改良された抗ＴｒｋＢ抗体
JP5677296B2 (ja) 2008-07-29 2015-02-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ グリオーマの治療のためのｃｄｋ阻害剤の使用
EP2350075B1 (fr) 2008-09-22 2014-03-05 Array Biopharma, Inc. Composés imidazo[1,2b]pyridazine substitués comme inhibiteurs de kinases trk
HUE057625T2 (hu) * 2008-10-22 2022-05-28 Array Biopharma Inc TRK kináz inhibitor szubsztituált pirazolo[1,5-a]pirimidin vegyületek
EP2376084B1 (fr) 2008-11-24 2013-07-17 Nerviano Medical Sciences S.r.l. Inhibiteur de CDK pour le traitement d'un mésothéliome
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
WO2011146336A1 (fr) 2010-05-20 2011-11-24 Array Biopharma Inc. Composés macrocycliques en tant qu'inhibiteurs de kinase trk
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
CA2828219A1 (fr) 2011-02-25 2012-08-30 Irm Llc Composes et compositions en tant qu'inhibiteurs de trk
RU2606131C2 (ru) 2011-05-13 2017-01-10 Эррэй Биофарма Инк. СОЕДИНЕНИЯ ПИРРОЛИДИНИЛМОЧЕВИНЫ И ПИРРОЛИДИНИЛТИОМОЧЕВИНЫ КАК ИНГИБИТОРЫ КИНАЗЫ TrkA
US20150306086A1 (en) 2011-11-14 2015-10-29 Tesaro, Inc. Modulating certain tyrosine kinases
EP2842955B1 (fr) 2012-04-26 2016-10-05 ONO Pharmaceutical Co., Ltd. Composé inhibiteur de trk
JP2013226108A (ja) * 2012-04-27 2013-11-07 Astellas Pharma Inc 新規ｎｔｒｋ２活性化変異の検出法
NZ703124A (en) 2012-05-23 2016-07-29 Nerviano Medical Sciences Srl Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
JP2014082984A (ja) * 2012-10-23 2014-05-12 Astellas Pharma Inc 新規ｎｔｒｋ２活性化変異の検出法
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078408A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés d'hétéroaryle urée, thiourée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
WO2014078325A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-aryle monocycliques, n'-pyrazolyl-urée, thiourée, guanidine et cyanoguanidine utiles comme inhibiteurs de trka kinase
NZ708028A (en) 2012-11-13 2018-12-21 Array Biopharma Inc N-pyrrolidinyl, n’-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078331A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-(arylalkyle)-n'-pyrazolyle-urée, de thiourée, de guanidine et de cyanoguanidine en tant qu'inhibiteurs de la kinase trka
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078417A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de pyrazolylurée, d'urée, de thiourée, de guanidine et de cyanoguianidine en tant qu'inhibiteurs de la trka kinase
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078322A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de thiazolyl-urée, oxazolyl-urée, thio-urée, guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
KR20150118148A (ko) 2013-02-19 2015-10-21 오노 야꾸힝 고교 가부시키가이샤 Trk 저해 화합물
EP3027655B1 (fr) 2013-07-30 2019-08-21 Blueprint Medicines Corporation Fusions de ntrk2
RS63829B1 (sr) 2014-01-24 2023-01-31 Turning Point Therapeutics Inc Diaril makrociklična jedinjenja kao modulatori protein kinaza
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
HUE045340T2 (hu) 2014-05-15 2019-12-30 Array Biopharma Inc 1-((3S,4R)-4-(3-fluorfenil)-1-(2-metoxietil)pirrolidin-3-il)-3-(4-metil-3-(2- metilpirimidin-5-il)-1-fenil-1H-pirazol-5-il)karbamid mint TrkA kináz inhibitor
JP5979335B2 (ja) 2014-08-18 2016-08-24 小野薬品工業株式会社 Ｔｒｋ阻害化合物の酸付加塩
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型

Also Published As

Publication number Publication date
MX2017015461A (es) 2018-08-15
IL256025A (en) 2018-01-31
KR20180021745A (ko) 2018-03-05
MA44936A1 (fr) 2021-09-30
AU2016270803A1 (en) 2018-01-04
CN107849615A (zh) 2018-03-27
CL2017003069A1 (es) 2018-06-01
US20180140604A1 (en) 2018-05-24
JP2018526324A (ja) 2018-09-13
CA2988423A1 (fr) 2016-12-08
PE20180329A1 (es) 2018-02-13
BR112017025773A2 (pt) 2018-08-14
EP3303631A1 (fr) 2018-04-11
EA201792679A1 (ru) 2018-06-29
HK1253093A1 (zh) 2019-06-06
WO2016196671A1 (fr) 2016-12-08
SV2017005577A (es) 2018-04-17
PH12017502200A1 (en) 2018-06-11
EP3722441A1 (fr) 2020-10-14
TN2017000502A1 (en) 2019-04-12
US20220088021A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
MA41667A1 (fr) Procede de diagnostic et de traitement du cancer
PH12018500902A1 (en) Point mutations in trk inhibitor-resistant cancer and methods relating to the same
MA34966B1 (fr) Fgfr et ses ligands utilisés comme biomarqueurs du cancer du sein chez des sujets rh positifs
MA43335B1 (fr) Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr
EP4293358A3 (fr) Composés organique volatiles utilisé comme biomarqueurs du cancer
MA32136B1 (fr) Procedes de diagnostic et de traitement de maladies mediees par parp
BR112018067882A2 (pt) métodos para diagnosticar e/ou monitorar lesão encefálica traumática em um indivíduo, para determinar se é apropriado administrar a um indivíduo uma terapia e para determinar um tratamento apropriado de um indivíduo, elemento sensor, sistema de detecção, kit, terapia, e, composição.
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
MX2018012856A (es) Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos.
WO2017070114A3 (fr) Biomarqueurs associés au diabète et de traitement d'affections associées au diabète
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
WO2019164402A8 (fr) Biocapteur bioluminescent pour la détection et la quantification de biomolécules
WO2015168602A3 (fr) Procédés et compositions pour le diagnostic et le traitement de la maladie de kawasaki
WO2017042625A3 (fr) Sous-typage moléculaire, pronostic et traitement du cancer de la prostate
MX2022014741A (es) Metodos para detectar bordetella.
EP4300101A3 (fr) Peptides antigéniques et leurs utilisations pour diagnostiquer et traiter l'autisme
MA38638B1 (fr) Marqueurs pour troubles liés à la sphingomyélinase acide et leurs utilisations
BR112019006404A2 (pt) métodos para diagnóstico e tratamento de câncer de próstata metastático resistente à castração sensível ou resistente a acetato de abiraterona-glicocorticoide
WO2017103001A3 (fr) Marqueurs diagnostiques de l'immunosénescence et procédés de détermination de la sensibilité aux infections nosocomiales
MX2016014779A (es) Prueba de diagnostico y tratamiento/prevencion de la enfermedad de alzheimer.
MA51893A (fr) Ligands de gm-csf ou du récepteur gm-csf destinés à être utilisés dans le traitement d'une malignité hématologique chez un patient ayant subi un allo-hct
Novikov et al. Positron emission tomography in giant cell arteritis: a new diagnostic tool?
RU2014113841A (ru) Способ ранней диагностики эндогенной интоксикации
EA201891693A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови
WO2021138273A3 (fr) Auto-anticorps en tant que biomarqueurs pour le syndrome polyglandulaire auto-immun de type 1